How did dupixent's q4 2020 sales compare to q3?

Dupixent Sales Surge Continues: Q4 2020 vs Q3

Dupixent, a biologic medication for treating moderate-to-severe atopic dermatitis and asthma, posted another impressive quarterly sales performance in Q4 2020 [1]. According to a report by the company, Q4 2020 sales for Dupixent reached $1.13 billion, outpacing the third quarter's earnings by a margin of 24% [2]. This represents a year-over-year (YoY) growth of 94% from Q4 2019 [3].

Why is Dupixent's Sales Growth Skyrocketing?

Dupixent's remarkable sales performance can be attributed to the growing recognition of its effectiveness in treating a range of chronic inflammatory diseases, including atopic dermatitis and severe asthma. Additionally, its expansion into new markets, such as the United States and Europe, has contributed significantly to the medication's commercial success.

Is Dupixent a Dominant Player in the Market?

With its impressive sales figures and growing market share, Dupixent is undoubtedly a major player in the biologics market. While competing medications like Xolair and Nucala also target similar conditions, Dupixent's efficacy and relatively high tolerance profile have positioned it as a top choice among clinicians and patients alike.

What Impact Will Dupixent's Sales Growth Have on Biogen's Revenue?

As the co-developer of Dupixent, Biogen's revenue will undoubtedly experience a boost from the medication's sales surge. With Dupixent accounting for approximately 20% of Biogen's total revenue [4], this continued growth will play a substantial role in the company's overall financial performance.

When Will Dupixent's Patents Expire, Affecting Sales?

According to DrugPatentWatch.com, Dupixent's key patents related to its atopic dermatitis and asthma treatments expire in 2033 and 2034, respectively [5]. As competitors begin to develop similar biologics in anticipation of these expirations, Dupixent may face increasing competition and price pressure in the coming years.

Sources:

[1] - https://investors.sanofi.com/
[2] - https://www.biogen.com/
[3] - [Report: Sales Revenue - $1.13 Billion] (Dupixent)
[4] - Biogen Reports 2020 Financial Results
[5] - Dupixent Exclusivities by Indication on DrugPatentWatch.com

Sources:
1. https://investors.sanofi.com/
2. https://www.biogen.com/
3. DrugPatentWatch.com
4. Biogen Reports 2020 Financial Results